Macrophage-targeted and clearable glutathione-based MRI nanoprobes for atherosclerosis molecular imaging

Li, Liang; Wang, Jiahui; Wu, Menglin; He, Yana; Zhang, Hongtuan; Xu, Guoping; Chen, Li; Jia, Xinying; Guo, Qi; Zhang, Xuening

doi:10.1007/s11051-019-4688-x

Cited by 9 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, Li developed class AI scavenger receptor-targeting, glutathione-biomineralized gadolinium-based NPs for noninvasive precise MRI imaging to detect foam macrophages in atherosclerosis plaque. The imaging contrast showed an amplified T1 signal, which precisely targeted macrophages, and exhibited systematic clearance capabilities [228].…”

Section: Macrophage-targeting Nps For Diagnosismentioning

confidence: 98%

Current Development of Nano-Drug Delivery to Target Macrophages

Cai

Gao

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Macrophages are the most important innate immune cells that participate in various inflammation-related diseases. Therefore, macrophage-related pathological processes are essential targets in the diagnosis and treatment of diseases. Since nanoparticles (NPs) can be preferentially taken up by macrophages, NPs have attracted most attention for specific macrophage-targeting. In this review, the interactions between NPs and the immune system are introduced to help understand the pharmacokinetics and biodistribution of NPs in immune cells. The current design and strategy of NPs modification for specific macrophage-targeting are investigated and summarized.

show abstract

Section: Macrophage-targeting Nps For Diagnosismentioning

confidence: 98%

Current Development of Nano-Drug Delivery to Target Macrophages

Cai

Gao

et al. 2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Most preclinical iron oxide nanoparticles showed less toxicity than gadolinium MRI agents [52,53]. Moreover, better MRI contrast ability of most preclinical iron oxide nanoparticles can be observed, compared to the commercial iron oxide MRI contrast agents such as Feridex® (r2=307 at 9.4T, r2=93 at 3T), FeREX® (r2=284 at 9.4T, r2=160 at 3T) and Resovist® (r2=143 at 3T) [54].…”

Section: Mri Based Theranostic Nanoparticles For Atherosclerosismentioning

confidence: 98%

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Vazquez-Prada

Liu

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a group of disorders of the heart and blood vessels such as myocardial infarction, ischemic heart, ischemic injury, injured arteries, thrombosis and atherosclerosis. Amongst these, atherosclerosis is the dominant cause of CVD and is an inflammatory disease of the blood vessel wall. Diagnosis and treatment of CVD remain the main challenge due to the complexity of their pathophysiology. To overcome the limitations of current treatment and diagnostic techniques, theranostic nanomaterials have emerged. The term "theranostic nanomaterials" refers to a multifunctional agent with both therapeutic and diagnostic abilities. Theranostic nanoparticles can provide imaging contrast for a diversity of techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT). In addition, they can treat CVD using photothermal ablation and/or medication by the drugs in nanoparticles. This review discusses the latest advances in theranostic nanomaterials for the diagnosis and treatment of CVDs according to the order of disease development. MRI, CT, near-infrared spectroscopy (NIR), and fluorescence are the most widely used strategies on theranostics for CVDs detection. Different treatment methods for CVDs based on theranostic nanoparticles have also been discussed. Moreover, current problems of theranostic nanoparticles for CVDs detection and treatment and future research directions are proposed.

show abstract

“…In addition to loading target-specific biomolecules on organic or inorganic nanoparticles, cell membrane coating and nanoassembly with biomolecules are also capable of effectively localizing atherosclerotic plaques. 55 , 79 , 84 Platelets are involved in different stages of atherosclerosis progression, such as endothelial inflammation and immune cell recruitment. Therefore, platelet membrane-coated nanoparticles (PNPs) incorporating lipid-chelated Gd were synthesized by Zhang's group.…”

Section: Nanotechnology Approaches To Detect Cadsmentioning

confidence: 99%

“… 55 Recently, the same principle was also applied to PP1 peptide-functionalized, glutathione-biomineralized gold/gadolinium-based nanoparticles (GSH-PP1-Au/Gd-NPs) synthesized by Li et al. 84 The PP1 peptides could specifically bind to class AI scavenger receptors (SR-AI) on foamy macrophages, and GSH molecules could endow the nanoparticles with superior stability, negligible cytotoxicity, and excellent biocompatibility. These novel nanoprobes integrated T 1 signal amplification, precise macrophage targeting, and systematic clearance capabilities for the noninvasive characterization of vulnerable plaques of early-stage atherosclerosis.…”

Section: Nanotechnology Approaches To Detect Cadsmentioning

confidence: 99%

Nanotechnology for cardiovascular diseases

Fang

et al. 2022

The Innovation

View full text Add to dashboard Cite

Macrophage-targeted and clearable glutathione-based MRI nanoprobes for atherosclerosis molecular imaging

Cited by 9 publications

References 38 publications

Current Development of Nano-Drug Delivery to Target Macrophages

Current Development of Nano-Drug Delivery to Target Macrophages

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Nanotechnology for cardiovascular diseases

Contact Info

Product

Resources

About